Abstract
Researchers in gene therapy have become extremely sensitive about perceived conflicts between their financial and scientific portfolios, following the death last year of a volunteer in a clinical trial at the University of Pennsylvania9s Institute for Human Gene Therapy (see main text). The trial used a technique for inserting genes into cells that was developed and patented by the institute9s head, James Wilson. Wilson and Penn itself have a financial stake in a company Wilson founded to develop the technology.

This publication has 0 references indexed in Scilit: